A Randomized, Endpoint-Blind, Parallel Group Study to Demonstrate the Non-Inferiority of the Subunit Influenza Vaccine Influvac® to the Subunit Influenza Vaccine Agrippal® in Healthy Children, Adults and Elderly in China.
Sponsor study identifier
interventional
900
1 country
1
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedIn the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy. In addition, safety and efficacy data with Influvac will be assessed in the Chinese population.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
May 11, 2006
Actual (reported)May 12, 2006
Actual (reported)HI titers 4 weeks after vaccination (efficacy) and safety and tolerability
HI derived parameters: seroprotection, seroconversion and mean fold increase 4 weeks after vaccination
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Site 1
Nanjing, China
Global Clinical Director Solvay
Solvay Pharmaceuticals
First Submitted
May 11, 2006
First Posted
May 12, 2006
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
November 1, 2006
Record last verified: 2006-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Individualized Motivational Print Materials to Encourage More Physical Activity
The Drug Facts Box: Helping Consumers Understand Drugs for Risk Reduction
Contact the study team to confirm eligibility.